Pharmacokinetics

Type: Keyphrase

Name: Pharmacokinetics

First reported 3 hours ago - Updated 3 hours ago - 1 reports

Clinical trials in progress targeting endogenous stem cells

Paris (France), June 2013 – The EndoStem consortium (www.endostem.eu), a large scale scientific collaboration coordinated by Dr David Sassoon (UPMC/Inserm, Paris, France), and co-financed by the European Commission via the 7th Framework Programme, has ... [Published Cordis - 3 hours ago]

Entities: Clinical trials, Stem Cell, Clinique, Patient, David Sassoon

First reported 4 hours ago - Updated 4 hours ago - 1 reports

An Effective Prodrug Strategy to Selectively Enhance Ocular Exposure of a Cannabinoid Receptor (CB1/2) Agonist

$ Novartis Institutes for Biomedical Research, Global Discovery Chemistry, 100 Technology Square, Cambridge, Massachusetts 02139, United States‡ Novartis Institutes for Biomedical Research, Metabolism and Pharmacokinetics, 250 Massachusetts Avenue, Cambridge, ... [Published Journal of Medicinal Chemistry - 4 hours ago]

Entities: Novartis Institutes for BioMedical Research, Prodrug, Cannabinoids, Pharmacokinetics, agonist

First reported 8 hours ago - Updated 8 hours ago - 1 reports

New NRTI BMS-986001 Potently Suppresses HIV in Early Monotherapy Study

BMS-986001, a novel thymidine nucleoside reverse transcriptase inhibitor (NRTI) being developed by Bristol-Myers Squibb, demonstrated good antiviral activity and appeared safe and well-tolerated in a 10-day monotherapy study, researchers reported in the ... [Published HIV and Hepatitis.com - 8 hours ago]

Entities: HIV/AIDS, thymidine, Antiviral, Pharmacokinetics

First reported 9 hours ago - Updated 9 hours ago - 1 reports

Eisai Co Ltd

Studies from Eisai Describe New Findings in Biological and Pharmaceutical Sciences

By a News Reporter-Staff News Editor at Biotech Week Investigators discuss new findings in Biological and Pharmaceutical Sciences. According to news originating from Ibaraki, Japan, by NewsRx correspondents, research stated, "Liposomes are drug delivery ... [Published Pharmacy Choice - 9 hours ago]

Entities: Eisai Co Ltd, liposomal, antineoplastic, Liposomes

First reported 16 hours ago - Updated 16 hours ago - 1 reports

Influence of mild and moderate liver impairment on the pharmacokinetics and metabolism of almorexant, a dual orexin receptor antagonist

This single-dose study aimed at investigating the effect of different degrees of hepatic impairment on the pharmacokinetics (PK), metabolism, and tolerability of almorexant, a first-in-class dual orexin receptor antagonist. Subjects with mild (Child-Pugh ... [Published Bionity.com - 16 hours ago]

Entities: hepatic, Pharmacokinetics, Receptor, Metabolism

First reported 20 hours ago - Updated 20 hours ago - 1 reports

Upcoming OGD Initiatives Address Regulatory Science Priority List

Upcoming pharmacokinetic studies, evaluations of drug product characterizations, and postmarketing assessments of therapeutic equivalence are among a handful of new initiatives being launched this year by the FDA’s Office of Generic Drugs (OGD) to address ... [Published FDA News - 20 hours ago]

Entities: Drug Product, Pharmacokinetics, Drugs

First reported Jun 18 2013 - Updated Jun 18 2013 - 5 reports

Hyperion Therapeutics Inc

Hyperion Therapeutics Announces Ravicti and Buphenyl Pharmacokinetic Analyses

Hyperion Therapeutics Announces RAVICTI and BUPHENYL Pharmacokinetic Analyses Reported in The Journal of Clinical Pharmacology SOUTH SAN FRANCISCO, Calif., June 18, 2013 (GLOBE NEWSWIRE) -- Hyperion Therapeutics, Inc.... ... [Published Drugs.com - Jun 18 2013]

Entities: Hyperion Therapeutics Inc, Buphenyl, Pharmacokinetics

First reported Jun 18 2013 - Updated Jun 18 2013 - 1 reports

Bioconcentration of Perfluorinated Alkyl Acids: How Important Is Specific Binding?

Perfluorinated alkyl acids (PFAAs) are important global pollutants with unique pharmacokinetics. Evidence is accumulating that their behavior within organisms is affected by interaction with a number of proteins. In mammals, serum albumin, fatty acid ... [Published Environmental Science & Technology - Jun 18 2013]

Entities: serum albumin, Proteins, Pharmacokinetics, Oat

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

2013-06-13 - Easier, more convenient cancer treatment for children

A new oral liquid formulation of two medicines has been developed in a ground-breaking EU-funded study. These medicines are used for the treatment of acute lymphoblastic leukaemia, the first cause of cancer in children.Although this leukaemia almost exclusively ... [Published Cordis - Jun 17 2013]

Entities: Active Ingredient, European Medicines Agency, Toxicity, Cancer

First reported Jun 16 2013 - Updated Jun 16 2013 - 1 reports

The Relevance Of Clinical Pharmacokinetic Investigations

Clinical Pharmacokinetics is a medical evaluation on the actual human body reactions upon drug serum concentration administration. This is crucial for the re-examination of already approved drugs and for the submission of new drug applications. This research ... [Published Article Motron - Jun 16 2013]

Entities: Pharmacokinetics, Drugs, Serum, investigational, Dosage

First reported Jun 15 2013 - Updated Jun 15 2013 - 1 reports

Influence of Low-Dose Ritonavir With and Without Darunavir on the Pharmacokinetics and Pharmacodynamics of Inhaled Beclomethasone

Objective: To identify an alternative inhaled corticosteroid to fluticasone propionate that can be safely coadministered with HIV protease inhibitors, the safety and pharmacokinetics of beclomethasone dipropionate (BDP) and its active metabolite, beclomethasone ... [Published JAIDS - Jun 15 2013]

Entities: Pharmacokinetics, ritonavir, beclomethasone, Darunavir

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

Pharmacokinetics Study of Recombinant Hirudin in the Plasma of Rats Using Chromogenic Substrate, ELISA, and Radioisotope Assays

by Su-yun Jiang, Jian Jiao, Ting-ting Zhang, Yong-ping XuAimTo compare the analytical methods used to study the pharmacokinetics of recombinant hirudin in the plasma of rats that had been injected with 125I-recombinant hirudin.Methods2.0 mg/kg 125I-recombinant ... [Published Elites TV - Jun 14 2013]

Entities: ELISA Enzyme-Linked Immunosorbent Assay, Recombinant, Pharmacokinetics, Substrate

Quotes

"Patients with CLL and SLL have a great need for new, well tolerated and effective therapies" said lead author John C Byrd

Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Publish ... [Published Street Insider - 2 hours ago]

...resulted in substantial decreases in plasma HIV-1 RNA levels for all dose groups and was generally well tolerated," the study authors concluded. "These data support continued clinical development of BMS-986001 at a dose of 100 mg, once-daily or greater."

New NRTI BMS-986001 Potently Suppresses HIV in Early Monotherapy Study [Published HIV and Hepatitis.com - 8 hours ago]

"It's exciting to be the new guy on the block," Riviere said. "I'm getting a similar sense from those I meet With Kansas State University, the Kansas City research industry, the upcoming National Bio and Agro-Defense Facility and Gov. Sam Brownback's support, everything is starting to line up for some really good opportunities in animal health."

Pharmacologist Creating Research Institute, Direction for Animal Health Industry's Future [Published Newswise - 8 hours ago]

...An abstract entitled, "Histological Assessment of Mouse Brains After 28-Day Chronic Oral Administration of Four Novel Neurogenic Compounds" was presented at the 2012 Annual Meeting for the Society of Neuroscience (SFN)...

The Neuralstem You Don't Know [Published Seeking Alpha - 8 hours ago]

More Content

sort by: Date \| Relevance
Ibrutinib Study Results in Patients with Relaps... [Published Street Insider - 2 hours ago]
NAPSR Proud To Announce: CNN Money Names Pharma... [Published Prlog - 3 hours ago]
Clinical trials in progress targeting endogenou... [Published Cordis - 3 hours ago]
An Effective Prodrug Strategy to Selectively E... [Published Journal of Medicinal Chemistry - 4 hours ago]
New NRTI BMS-986001 Potently Suppresses HIV in ... [Published HIV and Hepatitis.com - 8 hours ago]
Belrose Pharma Acquires Enzon’s Advanced Drug F... [Published Pharma - 8 hours ago]
Pharmacologist Creating Research Institute, Dir... [Published Newswise - 8 hours ago]
The Neuralstem You Don't Know [Published Seeking Alpha - 8 hours ago]
Amarin: FDA Panel Date, Misplaced Hype For Fixe... [Published TheStreet.com - 9 hours ago]
Studies from Eisai Describe New Findings in Bio... [Published Pharmacy Choice - 9 hours ago]
Study Data from School of Chemical and Biomolec... [Published Pharmacy Choice - 9 hours ago]
BioLineRx enrolls first patient in Phase II acu... [Published Individual.com - 11 hours ago]
Alios BioPharma initiates Phase 1 clinical tria... [Published Pharmacy Choice - 14 hours ago]
ARIAD Presents Updated Phase 1 Data on AP26113 ... [Published Pharmacy Choice - 14 hours ago]
Influence of mild and moderate liver impairment... [Published Bionity.com - 16 hours ago]
Upcoming OGD Initiatives Address Regulatory Sci... [Published FDA News - 20 hours ago]
ACADIA Issues Multiple Presentations of Data fr... [Published BioMedReports - Jun 19 2013]
Hyperion Therapeutics Announces Ravicti and Bup... [Published Drugs.com - Jun 18 2013]
Hyperion Therapeutics Announces Ravicti and Bup... [Published Big News Network - Jun 18 2013]
$40m fuding for SA Pathology’s Centre for Cance... [Published In-Business - Jun 18 2013]
Bioconcentration of Perfluorinated Alkyl Acids:... [Published Environmental Science & Technology - Jun 18 2013]
PhaseBio Pharmaceuticals, Inc. Expands Clinical... [Published BioSpace - Jun 18 2013]
Hyperion Therapeutics Announces RAVICTI and BUP... [Published BioSpace - Jun 18 2013]
Biodel Primed To Capitalize On Next Generation ... [Published Trefis - Jun 18 2013]
Mei Pharma Initiates Phase II Clinical Trial Of... [Published Barchart - Jun 18 2013]
Hyperion Therapeutics Announces RAVICTI and BUP... [Published Reuters - Jun 18 2013]
Civitas Therapeutics Receives Second Grant for ... [Published Street Insider - Jun 18 2013]
PhaseBio Expands Clinical Development of Vasome... [Published BioPortfolio - Jun 18 2013]
Hyperion Therapeutics Announces RAVICTI and BUP... [Published GlobeNewswire: Advertising News - Jun 18 2013]
Biodel Primed To Capitalize On Next Generation ... [Published Seeking Alpha - Jun 18 2013]

sort by: Date \| Relevance
Deuterated Drugs: An Obvious Idea? [Published In the Pipeline - Jun 10 2013] Nature Medicine has an update on the deuterated drug landscape. There are several compounds in the clinic, and the time to the first marketed deuterium-containing drug is surely counting down. But, as mentioned at the end of that piece, another ...
Protagonist Raises $14M to Expand Disulfide-Ric... [Published Pharma-Mag - Jun 04 2013] Firm says DRP candidates display benefits of both antibodies and small molecule drugs Protagonist Therapeutics raised $14 million in a Series B venture financing round led by new investor, Johnson & Johnson Development Corporation, and existing investors ...
Biotie Pays $1M for Option to Acquire Epilepsy ... [Published Pharma-Mag - Jun 04 2013] Firm’s lead drug candidate is an intranasal diazepam spray for treating epileptic seizures Biotie Therapies is paying Neurelis $1 million in cash to secure an exclusive option to acquire the latter outright through an $8.75 million shares-based deal, ...
BioAlliance presents results from pharmacokinet... [Published PBR - News - May 28 2013] BioAlliance Pharma has presented results from the pharmacokinetic and pharmacodynamic study on a mucoadhesive buccal tablet, known as Sitavig, at the 10th European Academy of Dermatology and Venereology symposium in Cracow, Poland. ...
Prosonix Initiates Phase 2 Clinical Study with ... [Published Pharma-Mag - May 22 2013] First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix’ particle engineering platform. Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory ...